Saturday, October 31, 2026

Groupon Stock Soars 14%+ In A Single Day: What's Driving The Surge?

ViaNews Editorial Team

October 13, 2023

Groupon Stock Soars 14%+ In A Single Day: What's Driving The Surge?

(VIANEWS) - Groupon stock jumped by 14.99% to EUR12.58 at 13:22 EST on Friday, extending gains seen over two sessions. Meanwhile, the NASDAQ index has dropped 1.17% and reached EUR13,414.99; suggesting an overall bearish trend in the market. Groupon closed at EUR10.94 last Thursday, marking a 32.68% decrease from its 52-week high of EUR16.25. Despite recent market uptick, Groupon remains trading well below this benchmark price. Recent stock gains may be attributable to positive company news or broader market movements; investors should exercise caution, however, given the negative trend in the market; it would be prudent for them to closely follow company performance and news developments as well as their performance.

About Groupon

Groupon is an online marketplace connecting consumers with local merchants, offering deals and discounts on goods and services. Operating across North America and international markets, Groupon sells on behalf of third-party merchants as well as selling its own first-party inventory through mobile apps and websites. Established as ThePoint.com in 2008 before being rebranded as Groupon the same year; Groupon now headquartered out of Chicago Illinois

Yearly Analysis

According to data provided, Groupon's stock is currently trading at EUR12.58 - significantly below its 52-week high of EUR16.25 but higher than its low of EUR2.89. This indicates a drastic price shift over the past year. Groupon is projected to experience sales growth estimated at negative 14.7% this year and 2.6% next year, which indicates revenue decrease while an expected partial rebound may take place over time. Groupon's EBITDA stands at EUR35.65, providing some insight into its overall profitability; however, without additional financial information it can be challenging to assess their overall health. Before making investment decisions, investors should carefully evaluate a company's competitive standing, management team, and long-term growth prospects before making their final choice.

Technical Analysis

Groupon stock has experienced an upward trajectory with current values significantly above its 50-day and 200-day moving averages, signalling strong bullish sentiment in the market for this stock. Additionally, its latest reported volume of 21,403,340 was 42.07% higher than its average volume; an encouraging sign for investors. Groupon has seen its volatility fluctuate significantly over the last quarter, with intraday variation averages ranging from negative 16.22% to positive 5.89% and its highest amplitude of average volatility reaching 19.68% during one week - an indication of increased uncertainty in the market. Additionally, Groupon's stock may currently be overbought (>=80), signaling potential correction in the near future. Groupon appears to be performing well; however, investors should remain wary of any possible pullback and keep a close eye on market sentiment for signs of shift.

Quarter Analysis

Groupon's financial performance shows both positive and negative indicators. Sales growth for both the current quarter and next quarter were negative - at -12.3% and -6.7%, respectively - which suggests revenue loss is occurring which should raise alarm among investors. However, the company's growth estimates for both this quarter and next quarter are significantly higher - at 116.2 and 173.77%, respectively. Although estimates can fluctuate depending on market forces and other variables, their optimism reveals something important about how management views its prospects of future success. At this point in time, year-on-year quarterly revenue growth for the company has declined 15.7%, reaching 543.27M over 12 trailing months. While this may seem negative at first glance, it's important to keep future estimates for growth into account when considering these numbers. Overall, investors should keep an eye on Groupon's financial performance over the coming quarters to assess its growth estimates and future growth potential. Conduct further research into its management team, competitive landscape and industry trends as necessary.

Equity Analysis

Groupon's trailing twelve months EPS was negative EUR3.3, suggesting it is not currently producing profits for shareholders. Furthermore, its return on equity (ROE) for this period was negative -309.27% indicating it is not making a return relative to equity invested by shareholders. Investors should exercise extreme caution when investing in Groupon due to its negative EPS and ROE figures, which indicate it may not currently be profitable or producing returns for shareholders. Investors should conduct further research and analysis in order to assess if Groupon's financial performance will improve in the future, and whether the stock would make an ideal addition to their portfolios.

More news about Groupon (GRPN).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com
Groupon Stock Soars 14%+ In A Single Day: What's Driving The Surge? | Via News